English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. Herein, we analyzed prostate cancer samples (majority metastatic) using comprehensive genomic profiling performed by next‐generation sequencing (315 genes, &gt;500× coverage) for alterations in activating and sensitizing cyclin genes ( CDK4  amplification,  CDK6  amplification,  CCND1 ,  CCND2 ,  CCND3 ,  CDKN2B  [loss],  CDKN2A  [loss],  SMARCB1 ), androgen receptor ( AR ) gene, and coalterations in genes leading to cyclin inhibitor therapeutic resistance ( RB1  and  CCNE1 ). Overall, cyclin sensitizing pathway genomic abnormalities were found in 9.7% of the 5,356 tumors. Frequent alterations included  CCND1  amplification (4.2%) and  CDKN2A  and B loss (2.4% each). Alterations in possible resistance genes,  RB1  and  CCNE1 , were detected in 9.7% (up to 54.6% in neuroendocrine) and 1.2% of cases, respectively, whereas  AR  alterations were seen in 20.9% of tumors (~27.3% in anaplastic). Cyclin sensitizing alterations were also more frequently associated with concomitant  AR  alterations.

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics